Oxybuprocaine
Based on 1 Customer Validation
Oxybuprocaine is a short-acting ester anesthetic. Oxybuprocaine binds to sodium channels and reversibly stabilizes neuronal membranes. Oxybuprocaine has cutaneous analgesic properties. Oxybuprocaine is less potent than Bupivacaine (HY-B0405) at producing central nervous system and cardiovascular toxicity. Oxybuprocaine can be used in ophthalmology and otolaryngology.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.93%
- CAS 番号: 99-43-4
- 分子式: C17H28N2O3
- 分子量:308.42
-
保管条件:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Rare Diseases Drug Library
HY-L102
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Human Metabolite Library
HY-L123
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Ion Channel Compound Library
HY-L166
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
生物活性
Oxybuprocaine (6.67 μmol/kg/min; i.v.) hydrochloride produces slower decreases in mean arterial blood pressure and heart rate compared with Bupivacaine (HY-B0405) in Sprague-Dawley rats, and the time to induce seizure, apnea, and impending death is longer than that of Bupivacaine[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 99-43-4
-
性状 Viscous Liquid
-
分子量 308.42
-
分子式 C17H28N2O3
-
Color Colorless to light yellow
-
SMILES
O=C(OCCN(CC)CC)C1=CC=C(N)C(OCCCC)=C1
-
別名
Benoxinate; Novesinol; Oxybucaine
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
DMSO : ≥ 125 mg/mL (405.29 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (270 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Masayuki Kohsaka, et al. Oxybuprocaine for apraxia of lid opening in Parkinson's disease: A placebo-controlled pilot trial. Mov Disord [Content Brief]
[2]. Nam SM, et al. Comparison of corneal thickness after the instillation of topical anesthetics: proparacaine versus oxybuprocaine. Cornea. 2006 Jan;25(1):51-4. [Content Brief]
[3]. Tomaciello F, et al. Resveratrol lacks protective activity against acute seizures in mouse models. Neurosci Lett. 2016 Oct 6;632:199-203. [Content Brief]
[4]. Hung CH, et al. The systemic toxicity of equipotent proxymetacaine, oxybuprocaine, and bupivacaine during continuous intravenous infusion in rats. Anesth Analg. 2010 Jan 1;110(1):238-42. [Content Brief]
[6]. Dong Z, et al. Efficacy and Safety of Oxybuprocaine Hydrochloride Gel in Alleviating Pain during Male Urethral Catheterization: A Single-Center Randomized Controlled Study. Int J Clin Pract. 2022 Sep 14;2022:5734387. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2423 mL | 16.2117 mL | 32.4233 mL | 81.0583 mL |
| 5 mM | 0.6485 mL | 3.2423 mL | 6.4847 mL | 16.2117 mL | |
| 10 mM | 0.3242 mL | 1.6212 mL | 3.2423 mL | 8.1058 mL | |
| 15 mM | 0.2162 mL | 1.0808 mL | 2.1616 mL | 5.4039 mL | |
| 20 mM | 0.1621 mL | 0.8106 mL | 1.6212 mL | 4.0529 mL | |
| 25 mM | 0.1297 mL | 0.6485 mL | 1.2969 mL | 3.2423 mL | |
| 30 mM | 0.1081 mL | 0.5404 mL | 1.0808 mL | 2.7019 mL | |
| 40 mM | 0.0811 mL | 0.4053 mL | 0.8106 mL | 2.0265 mL | |
| 50 mM | 0.0648 mL | 0.3242 mL | 0.6485 mL | 1.6212 mL | |
| 60 mM | 0.0540 mL | 0.2702 mL | 0.5404 mL | 1.3510 mL | |
| 80 mM | 0.0405 mL | 0.2026 mL | 0.4053 mL | 1.0132 mL | |
| 100 mM | 0.0324 mL | 0.1621 mL | 0.3242 mL | 0.8106 mL |
Oxybuprocaine 関連分類
HY-B1288A 関連分類
Powered by Bioz